close
close

JP Morgan Life Sciences Private Capital Closes Inaugural Biotechnology Venture Capital Fund with More Than $500 Million in Commitments

NEW YORK, June 13, 2024 /PRNewswire/ — JP Morgan private capital, a venture capital and growth capital investment team within JP Morgan Asset Management today announced the final closing of the inaugural Life Sciences Private Capital issuance, 270 Life Sciences Private Capital Fund I (the foundation”)led by Chief Investment Officer Stephen Squinto, Ph.D. and Managing Partner Gaurav Gupta, MD, MSE The fund closed above its $500 million goal, and has strong support from investors, including institutional allocators, strategic corporate partners, family offices and high-net-worth individuals North America, Europethe Middle EastAnd Asiaas well as JPMorgan Chase & Co.

“We are pleased to announce the closing of our first fund, which has been raised in just over a year, almost twice as fast as our peers in the past decade1,” said Dr. Stephen SquintoChief Investment Officer and Managing Partner of JP Morgan Life Sciences Private Capital. “As investors and business builders, we at JP Morgan Private Capital are strongly positioned to identify and back highly innovative companies that can shape the future of how patients are treated. Our mission is not only to capitalize companies, but also to to leverage our collective experience to guide them to successful outcomes, and to mentor a new generation of biotechnology founders and executives.”

The Fund invests in private biotechnology companies across stage, modality, therapeutic area and geography. The Fund’s early business formation activities and portfolio investments include cardiometabolic diseases, oncology, immunology and genetic medicines. The Fund also aims to leverage JP Morgan’s size and resources to add value to portfolio companies.

“We are grateful for the support of our investors and for the important contributions of our strategic advisors and internal team members as we announce the closing of our first life sciences venture capital fund. As the biotechnology industry enters the next era of scientific discovery, we strive aims to become a partner of choice for world-class researchers and entrepreneurs,” the organization said Gaurav GuptaMD, MSE, Managing Partner of JP Morgan Life Sciences Private Capital.

About JP Morgan Private Capital

JP Morgan Private Capital provides customized financing solutions for private companies across the capital structure, with an emphasis on venture and growth investments. The platform’s solutions span the consumer, technology and life sciences sectors. JP Morgan Private Capital has a technology and consumer fund; JP Morgan Growth Equity Partners, with 1 billion dollars in the total commitments received April 2023. In addition, a venture capital fund for biotechnology; 270 Life Sciences Private Capital Fund I, with more than 500 million dollars in the total commitments received June 2024.

JP Morgan Private Capital is part of JP Morgan Global Alternatives, the alternative investment arm of JP Morgan Asset Management. With more than 60 years of experience in managing alternative investments, $214 billion in managed assets and more than 800 professionals (from March 31, 2024), its strategies cover the full spectrum of alternatives: real estate, private equity, private credit, liquid alternative products, infrastructure, transportation, hedge funds and forestry. From America, Europe And Asiaindependent alternative investment teams combine their advanced expertise with JP Morgan’s resources, infrastructure and global reach to achieve each client’s specific objectives. For more information: jpmorgan.com/am

About JP Morgan Asset Management

JP Morgan Asset Management, with assets under management $3.1 trillion (from December 31, 2023), is a global leader in investment management. JP Morgan Asset Management clients include institutions, private investors and high net worth individuals in all major markets around the world. JP Morgan Asset Management provides global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information: www.jpmorganassetmanagement.com. JP Morgan Asset Management is the marketing name for the asset management activities of JPMorgan Chase & Co. and its subsidiaries worldwide.

JPMorgan Chase & Co. (the “Company”) (NYSE: JPM) is a leading financial services company based in the United States of America (“US”), with operations worldwide. JPMorgan Chase does $3.9 trillion in assets and $328 billion in equity from December 31, 2023. The company is a leader in investment banking, consumer and small business financial services, commercial banking, financial transaction processing and asset management. Under the JP Morgan and Chase brands, the company serves millions of customers in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.


1 Preqin, 2024. Includes the first healthcare venture capital funds launched between 2014 and 2024.

SOURCE JP Morgan Asset Management